Table 1.
Demographic and clinicopathological characteristics of our study population (n = 100 patients)
| Variables | Median (range) or n (%) |
|---|---|
| Demographics | |
| Age (years) | 44 (21–71) |
| Body mass index (kg/m2) | 24.9 (17.6–35.3) |
| Gender | |
| Female | 89 (89 %) |
| Male | 11 (11 %) |
| Laboratory values | |
| ASAT (µmmol/l) | 0.39 (0.2–1.15) |
| ALAT (µmmol/l) | 0.36 (0.15–1.7) |
| y-glutamyltransferase (µmmol/l) | 1.4 (0.1–9.6) |
| Bilirubin (µmol/l) | 8.7 (2–30) |
| Alkaline phosphatase (µmol/l) | 2.5 (0.7–7.1) |
| Prothrombin time (%) | 104 (58–134) |
| Pathology | |
| Typical FNH | 80 (80 %) |
| Non-classical FNH | 20 (20 %) |
| Tumor size (cm) | 5.9 (2–17) |
| Tumor distribution | |
| Unilobular | 76 (76 %) |
| Multilobular | 24 (24 %) |
| Tumor weight (g) | 366.5 (10–1886) |
| Number of tumor lesions | 1.59 (1–7) |
| Medical history | |
| Previous hormone therapy | |
| Yes | 67 (67 %) |
| No | 33 (33 %) |
| Median time of hormone use (years) | 18 (1–35) |
| Other medicaments (aspirine, steroids, antidepressants) | 14 (14 %) |
| History of cancer | |
| Yes | 18 (18 %) |
| No | 82 (82 %) |